BlackRock Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

BlackRock Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$737K	Sell	12,933 -500	-4%	-$30.2K	﹤0.01%	1998
2016 Q3	$835K	Buy	13,433 +1,097	+9%	+$77.5K	﹤0.01%	1915
2016 Q2	$698K	Buy	12,336 +7,137	+137%	+$434K	﹤0.01%	1941
2016 Q1	$333K	Hold	5,199	–	–	﹤0.01%	2287
2015 Q4	$731K	Sell	5,199 -6,397	-55%	-$869K	﹤0.01%	1892
2015 Q3	$1.12M	Sell	11,596 -19,000	-62%	-$2.26M	﹤0.01%	1609
2015 Q2	$4.64M	Buy	+30,596	New	+$5.05M	﹤0.01%	1011

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Advisors's KDNY Position: Q4 2016 in Review

BlackRock Advisors reduced its Chinook Therapeutics, Inc. Common Stock (KDNY) stake by 3.7% in Q4 2016, selling an estimated $30.2K and leaving 12,933 shares worth $737K. The position accounts for ﹤0.01% of the portfolio, ranked #1998.

BlackRock Advisors first reported a position in KDNY in Q2 2015 and has held it in 7 quarters since. The position peaked at $4.64M in Q2 2015. 87 funds tracked by Wall St. Rank hold KDNY as of Q4 2016.

BlackRock Advisors held 12,933 shares of Chinook Therapeutics, Inc. Common Stock worth $737K as of Q4 2016.
BlackRock Advisors sold 500 Chinook Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $30.2K.
Chinook Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1998 holding.
BlackRock Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $4.64M in Q2 2015.
87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.